An Fc-Engineered Humanized Anti-CD40 Monoclonal Antibody, XmAb5485, Exhibits Potent Activity in Vitro and in Vivo against Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma

抗体依赖性细胞介导的细胞毒性 慢性淋巴细胞白血病 癌症研究 免疫学 抗体 多发性骨髓瘤 单克隆抗体 白血病 医学
作者
Eugene A. Zhukovsky,Holly M. Horton,Matthias Peipp,Erik Pong,Matthew J. Bernett,Sher Karki,John O. Richards,Seung Y. Chu,Roland Repp,John R. Desjarlais
出处
期刊:Blood [Elsevier BV]
卷期号:112 (11): 881-881 被引量:2
标识
DOI:10.1182/blood.v112.11.881.881
摘要

Abstract CD40, a transmembrane glycoprotein belonging to the tumor necrosis factor receptor family, is an attractive target for cancers of lymphoid origin since it is expressed on most mature B-cell malignancies, some early B-cell acute lymphocytic leukemias, and multiple myeloma. Finding efficient therapies for multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and rituximab-refractory Non-Hodgkin Lymphoma (NHL) represents an unmet need. Several anti-CD40 antibodies, both agonistic and antagonistic, have demonstrated objective responses in early clinical NHL trials and thus validated this antigen as a target for lymphoproliferative diseases. Here we present the characterization of a novel Fc-engineered and humanized anti-CD40 antibody, XmAb®5485, that was generated using our XmAb antibody engineering technology. This antibody is highly cytotoxic against lymphoma, leukemia and multiple myeloma cell lines as well as primary cancer cells. XmAb5485 is characterized by: i) increased affinity for Fc gamma receptors (FcgR), ii) improved effector function, and iii) significantly increased antitumor potency. We investigated several direct and indirect (Fc-mediated) mechanisms of antibody-mediated cytotoxicity in vitro. The potency (EC50) of XmAb5485 in antibody-dependent cell-mediated cytotoxicity (ADCC) increased up to 150-fold relative to the native non Fc-engineered version (anti-CD40 IgG1) of the antibody in a screen of Burkitt’s lymphoma [BL], CLL and MM-derived cell lines. In the same cell lines, ADCC potency and maximal efficacy (% lysis) of XmAb5485 were also superior to that of rituximab: 74- and 1.3-fold higher in CLL, 12.5- and 1.4-fold higher in BL, and 190- and 1.9-fold higher in MM. In a MM cell line with low density of CD40 expression (~3500 per cell) XmAb5485 facilitated efficient ADCC whereas anti-CD40 IgG1 was virtually ineffective. Furthermore, using a BL cell line (Ramos) XmAb5485 displayed antibody-dependent cellular phagocytosis (ADCP) with potency and efficacy increased relative to rituximab (15- and 1.6-fold) and anti-CD40 IgG1 (5- and 1.2-fold). XmAb5485 also exhibited anti-proliferative apoptotic activity that was similar to that of rituximab. Ex vivo, XmAb5485 mediated potent ADCC of multiple primary patient-derived CLL, MCL, and plasma cell leukemia (PCL, an aggressive form of MM) cells, with substantially increased potency and efficacy relative to rituximab; in contrast, anti-CD40 IgG1 displayed minimal or no activity in these primary tumor cells. In vivo, in an established large (210–350 mm3) sc Ramos tumor xenograft model, 6 mg/kg XmAb5485 cured 80% of mice of detectable tumors and displayed statistically significant superiority over anti-CD40 IgG1. In contrast, only 7% of animals in the rituximab cohort were cured. In summary, our data suggest that XmAb5485, an anti-CD40 Fc variant antibody engineered for increased effector function, is a promising next-generation immunotherapeutic for leukemias, lymphomas, and multiple myeloma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
粗心小熊猫完成签到,获得积分10
刚刚
151515完成签到,获得积分10
1秒前
赘婿的应助被先玉梅采纳,获得30
1秒前
单杀是发布了新的文献求助10
1秒前
lilysmile001完成签到,获得积分10
1秒前
脑洞疼的应助被勤恳的丹翠采纳,获得10
2秒前
明理芫发布了新的文献求助10
3秒前
聪慧的稀发布了新的文献求助10
3秒前
zcyuqing发布了新的文献求助10
4秒前
田様的应助被luori_2000采纳,获得100
4秒前
5秒前
思源的应助被asahi采纳,获得10
5秒前
Owen的应助被小巧紫蓝采纳,获得10
5秒前
lili驳回了SciGPT的应助
5秒前
5秒前
伶俐微笑完成签到,获得积分20
6秒前
混世魔王完成签到,获得积分10
7秒前
王小茗完成签到,获得积分10
7秒前
Again关注了科研通微信公众号
7秒前
9秒前
miemie完成签到,获得积分10
9秒前
Eidden_Zhang发布了新的文献求助10
10秒前
gongjie完成签到 ,获得积分10
10秒前
10秒前
K红豆完成签到,获得积分10
10秒前
11秒前
vary完成签到,获得积分20
11秒前
诗蕊发布了新的文献求助10
13秒前
大个的应助被Gxr采纳,获得10
13秒前
13秒前
che66完成签到,获得积分20
13秒前
wanci的应助被单杀是采纳,获得10
14秒前
14秒前
ansi完成签到,获得积分10
14秒前
赘婿的应助被老实的盼芙采纳,获得10
15秒前
xinyuanjia的应助被akakns采纳,获得10
16秒前
Chow完成签到,获得积分10
16秒前
小马甲的应助被先玉梅采纳,获得10
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163407
求助须知:如何正确求助?哪些是违规求助? 9557533
关于积分的说明 21740746
捐赠科研通 7754041
什么是DOI,文献DOI怎么找? 3428210
关于科研通互助平台的介绍 2552932
邀请新用户注册赠送积分活动 2472896